Holen Sie sich die Stockscreener-App
1.76
1.73%
0.03
Handel nachbörslich:
1.79
0.03
+1.70%
Essa Pharma Inc Aktie (EPIX) Neueste Nachrichten
Piper Sandler Downgrades ESSA Pharma (EPIX) - MSN
United States shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
Thinking about buying stock in Adverum Biotechnologies, Roma Gre - GuruFocus.com
Oppenheimer Downgrades ESSA Pharma (EPIX) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc.EPIX - PR Newswire
PFM Health Sciences, LP Adjusts Stake in ESSA Pharma Inc - GuruFocus.com
RTW INVESTMENTS, LP Acquires Shares in ESSA Pharma Inc - GuruFocus.com
ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
ESSA Pharma And 2 Other US Penny Stocks To Watch - Yahoo Finance
Jones Trading Downgrades ESSA Pharma (EPIX) - MSN
ESSA Pharma (NASDAQ:EPIX) Lowered to Market Perform Rating by Oppenheimer - Defense World
ESSA Pharma (NASDAQ:EPIX) Rating Lowered to Neutral at Piper Sandler - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Growth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) Stock - MarketBeat
Bb biotech ag sells Essa Pharma shares for $12 million - Investing.com
Bb biotech ag sells Essa Pharma shares for $12 million By Investing.com - Investing.com UK
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ESSA Pharma shares downgraded after halting drug development By Investing.com - Investing.com Canada
ESSA Pharma terminates vital trial, leading Piper Sandler to cut shares rating - Investing.com Canada
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials - Investing.com Canada
Jefferies Financial Group Downgrades ESSA Pharma (NASDAQ:EPIX) to Hold - MarketBeat
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect | NDAQ:EPIX | Press Release - Stockhouse Publishing
Michael Jenson, PA-C, on Minnesota Urology’s Surgical Impotence Management Strategy program - Urology Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect - AccessWire
ESSA Pharma tank as it drops Phase II masofaniten study - The Pharma Letter
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
ESSA Pharma stock plunges to 52-week low of $1.55 - Investing.com India
ESSA Pharma stock plunges to 52-week low of $1.55 By Investing.com - Investing.com South Africa
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Essa ends prostate cancer bid, seeks strategic options - BioWorld Online
ESSA Pharma tanks after terminating trial for its prostate cancer treatment - MSN
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results - Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results - Benzinga
ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC - OncLive
Dow Jumps 400 Points; US Adds 12,000 Jobs In October - Benzinga
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data - Investing.com Australia
Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade - Barchart
Why Is ESSA Pharma Stock Plunging On Friday?ESSA Pharma (NASDAQ:EPIX) - Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
ESSA Pharma tanks after terminating trial for its prostate cancer treatment (NASDAQ:EPIX) - Seeking Alpha
Jones Trading cuts ESSA Pharma shares to hold from buy on trial data By Investing.com - Investing.com South Africa
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment - Yahoo Finance
Essa Pharma Shares Drop After Lead Drug Candidate Fails - MarketWatch
ESSA Pharma (NASDAQ:EPIX) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - VictoriaNow
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - StockTitan
When the Price of (EPIX) Talks, People Listen - Stock Traders Daily
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k - Yahoo Finance
ESSA Pharma Insiders Added US$709.0k Of Stock To Their Holdings - Simply Wall St
ESSA Pharma (NASDAQ:EPIX) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Centessa Pharmaceuticals (CNTA) - RTTNews
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):